Therefore, in the past 2 years, various combinations of ICI and anti-VEGF monoclonal antibodies have been the research focus of HCC-targeted therapy, which has greatly improved the survival rate of advanced HCC patients and created a new combination for targeted therapy (Ouyang et al., 2022). This evidence concerns the gene VEGFA and hepatocellular carcinoma.